Use of GXII Platform in HT Screening for Mammalian ... - PerkinElmer
Use of GXII Platform in HT Screening for Mammalian ... - PerkinElmer
Use of GXII Platform in HT Screening for Mammalian ... - PerkinElmer
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Case Study: Prote<strong>in</strong> Fragment production<br />
% Integrity<br />
100.0<br />
90.0<br />
80.0<br />
70.0<br />
60.0<br />
50.0<br />
40.0<br />
30.0<br />
20.0<br />
10.0<br />
0.0<br />
0.0 1.0 2.0 3.0 4.0 5.0<br />
Time (Hours)<br />
• Manufactur<strong>in</strong>g process<br />
required rapid antibody<br />
<strong>in</strong>tegrity test<strong>in</strong>g<br />
• Not possible by standard<br />
techniques (SDS PAGE)<br />
• Allowed decision mak<strong>in</strong>g<br />
driven by data to obta<strong>in</strong><br />
optimum yield<br />
Aggregate (>200 kDa)<br />
Prote<strong>in</strong> XS1 (160 to 140 kDa)<br />
Product (106 kDa)<br />
Fragment A (100 to 92 kDa)<br />
Fragments B (90 to 30 kDa)<br />
© Lonza Biologics plc 2012 slide 22
Change language